Zota Health Care Peer Comparison

NSE: ZOTA

₹1,324.00

₹50.40 (3.96%)

As on 11-Nov-2026IST

Market cap

₹4,585 Cr

Revenue (TTM)

₹679 Cr

P/E Ratio

P/B Ratio

7.4

Div. Yield

0.1 %

Edit

	Zota Health Care	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	4,585	32,651	33,066	32,103	28,572
Revenue (₹ Cr)	679	9,779	3,751	1,593	2,100
Net Profit (₹ Cr)	-114.01	-270.51	405.00	438.64	324.79
Net Margin (%)	-16.50	-2.71	10.48	27.16	15.36
RoE (%)	-21.72	-2.55	7.91	25.02	24.02
Price to Earnings	--	--	80.65	73.10	87.96
Price-To-Book	7.35	4.01	6.41	17.28	20.17

Income Statement (₹ Cr)

	Zota Health Care	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Operating Revenue	679.06	9,778.62	3,751.00	1,592.52	2,100.17
Total Income	690.88	9,993.26	3,863.00	1,615.23	2,114.53
Total Expenditure	679.34	8,578.44	2,984.00	969.32	1,600.14
EBITDA	-0.28	1,200.18	767.00	623.20	500.03
Depreciation	105.68	887.82	228.00	41.96	57.00
EBIT	-105.96	312.36	539.00	581.24	443.03
Interest	23.00	347.94	218.00	4.21	40.83
Other Income	11.83	214.64	112.00	22.71	14.37
Exceptional Items	-6.00	-216.88	12.00	0.00	0.00
Profit before Tax	-123.13	-37.82	445.00	599.74	416.57
Provision for Tax	-9.12	232.69	40.00	161.10	91.78
Profit after Tax	-114.01	-270.51	405.00	438.64	324.79

	Zota Health Care	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	693.49	8,142.24	5,158.00	1,857.45	1,416.33
Minority Interest	1.21	0.55	5.00	0.51	0.05
Non-Current Liabilities	197.61	5,213.99	1,617.00	47.15	376.76
Current Liabilities	237.27	5,158.51	1,785.00	253.37	952.98
Total Liabilities	1,131.05	17,723.32	8,578.00	1,983.96	2,326.71

	Zota Health Care	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Non-Current Assets	449.53	10,687.30	5,527.00	1,132.12	798.30
Current Assets	457.17	7,253.65	2,764.00	1,012.00	1,747.21
Total Assets	1,131.05	17,723.32	8,578.00	1,983.96	2,326.71
Total Debt*	28.73	5,495.48	2,125.00	26.49	259.37
Net Current Assets	219.89	2,095.14	979.00	758.64	794.23
Contingent Liabilities	--	95.72	768.26	17.25	19.09

	Zota Health Care	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	-81.85	1,652.60	390.00	292.17	205.05
Cash Flow from Investing Activities	-329.64	-826.03	-241.00	-265.94	-409.72
Cash from Financing Activities	503.44	-38.98	-54.00	4.10	283.07
Net Cash Inflow / Outflow	91.95	787.59	95.00	30.33	78.39

	Zota Health Care	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
ROCE (%)	-13.12	1.24	6.79	32.42	29.22
ROE (%)	-21.72	-2.55	7.91	25.02	24.02
ROA (%)	-14.52	-1.56	4.65	22.40	14.30
EBIT Margin (%)	-15.60	3.19	14.37	36.50	21.09
Net Margin (%)	-16.50	-2.71	10.48	27.16	15.36
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Zota Health Care	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	68.95	9.43	25.70	45.18	46.25
EBIT Growth (%)	-103.08	-3.72	139.56	115.51	60.95
Net Profit Growth (%)	-84.47	-199.34	894.12	95.80	89.41
EPS Growth (%)	-49.63	-410.28	599.72	63.29	76.32
Book Value Growth (%)	210.03	0.33	13.47	26.03	144.31

	Zota Health Care	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Price / Earnings	-41.56	-157.01	82.76	73.10	87.78
Price / Book Value	7.35	4.01	6.41	17.28	20.17
Dividend Yield (%)	0.08	0.00	0.00	0.06	0.09
EV/EBITDA	-16,430.93	30.65	45.02	51.19	56.97
Market Cap (₹ Cr)	3,687.70	18,108.89	19,071.62	20,944.75	12,753.19

	Zota Health Care	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.01	0.55	0.28	0.02	0.13
Short term debt to equity ratio	0.03	0.09	0.09	0.00	0.05
Current Ratio	1.93	1.41	1.55	3.99	1.83
Quick Ratio	1.11	0.77	1.00	2.89	1.00
Interest Coverage	-4.35	0.89	3.04	143.52	11.20

	Zota Health Care	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	10.83	23.05	16.85	22.50	27.51
Asset Turnover	0.86	0.56	0.43	0.81	0.92
Receivable days	38.63	78.20	58.75	88.98	40.13
Inventory Days	101.07	93.30	75.82	56.04	60.29
Payable days	125.38	226.14	186.21	99.95	232.47
Cash Conversion Cycle	14.33	-54.64	-51.64	45.07	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.